Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) Diagnosed by Controlled Attenuation Parameter on Transient Elastography and Its Predisposing Factors in Psoriasis

Abstract

Background: Psoriasis patients have an increased risk for non-alcoholic fatty liver disease (NAFLD). Controlled attenuation parameter (CAP) on transient elastography is more sensitive than abdominal ultrasonography in detecting liver steatosis. Objectives: To determine the prevalence of NAFLD in psoriasis and to identify its predisposing factors. Methods: A cross-sectional study was performed involving 109 psoriasis patients aged > 18 years in two tertiary dermatology clinics in Kuala Lumpur. Patients on hepatotoxic drugs, had excessive alcohol intake, and other secondary causes of chronic liver diseases were excluded. Anthropometrics, blood pressure, Psoriasis Area and Severity Index (PASI), liver function test, lipid profile, and fasting blood glucose were obtained. CAP on transient elastography was performed to diagnose NAFLD. The clinical characteristics of psoriasis patients were compared between patients with and without NAFLD. Results: The prevalence of NAFLD was 85.3%. NAFLD in psoriasis patients was associated with a higher weight (P < 0.0005), body mass index (BMI) (P < 0.0005), waist circumference (P < 0.0005), and metabolic syndrome (P = 0.002). Fasting blood glucose (5.3

Prevalence and risk of nonalcoholic fatty liver disease among adult psoriatic patients: A systematic review, meta-analysis, and trial sequential analysis

“…Forty-one studies [12–14,18,33–69] were included in the meta-analysis that 19 studies were case–control studies and 22 studies had no control groups (Table 1).…”

“…Gaspari, 2016 [57] Italy Caucasian 33/53 -54.8 PsA Not described Madanagobalane, 2012 [18] India Xu, 2017 [69] China Asian 250/439 -45.6 MSP US, liver test, exclusion of other liver diseases Torbator, 2022 [67] UK Caucasian 30/57 -55.5 NR US, liver test, exclusion of other liver diseases Tsai, 2011 [14] Taiwan Asian 223/51,800 434/207,200 46.4 MSP ICD Farias, 2011 [52] Chile Mixed 14/100 138/4928 43 NR Not described Kamil, 2019 [64] Malaysia Asian 93/109 -53 NR US, liver test, exclusion of other liver diseases Van Der Voort, 2016 [68] Netherlands Three previous meta-analyses [22][23][24] reported the association of NAFLD in psoriatic patients. One meta-analysis [23] suggested that the association was independent of confounding factors and body mass index, Psoriatic Area Severity Index scores, and liver function test components were significant risk factors for the association.…”

Effect of low-calorie diet on psoriasis severity index, triglycerides, liver enzymes, and quality of life in psoriatic patients with non-alcoholic fatty liver disease

“…Non-alcoholic fatty liver disease (NAFLD) is one of the highly prevalent metabolic diseases/complications in patients with psoriasis, especially obese ones [ 2 , 3 ]. The estimated percentage of NAFLD in patients with psoriasis is 85% [ 4 , 5 ] but the cause of this high percentage is not fully explained [ 6 ].…”

Preventative and Therapeutic Effects of Astaxanthin on NAFLD

“…NAFLD is expected to take on a predominant role as the leading aetiology of advanced liver disease in the forthcoming decades [ 1 ]. NAFLD is a condition that progresses from simple fatty liver (steatosis) to a severe form of non-alcoholic steatohepatitis (NASH) [ 2 ], which can result in irreparable organ damage, liver fibrosis, and hepatocellular carcinoma (HCC) in rare instances [ 3 ]. In general, an unbalanced diet and a lack of physical activity are the main causes of NAFLD [ 4 ].…”